67 related articles for article (PubMed ID: 8608049)
1. Economic analysis during phase III clinical trials: who, what, when, where, and why?
Bennett CL; Westerman IL
Oncology (Williston Park); 1995 Nov; 9(11 Suppl):169-75. PubMed ID: 8608049
[TBL] [Abstract][Full Text] [Related]
2. Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed lymphoid malignancy: implications for economic analyses of phase III clinical trials.
Bennett CL; George SL; Vose JM; Nemunaitis JJ; Armitage JL; Armitage JO; Gorin NC; Gulati SC
Stem Cells; 1995 Jul; 13(4):414-20. PubMed ID: 7549900
[TBL] [Abstract][Full Text] [Related]
3. Factors to consider when designing phase III clinical trials involving economic evaluations.
van Enckevort PJ; TenVergert EM; Kingma J; Koëter GH; Rutten FF
Percept Mot Skills; 1999 Dec; 89(3 Pt 2):1059-72. PubMed ID: 10710753
[TBL] [Abstract][Full Text] [Related]
4. Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials.
Bennett CL; Smith TJ; George SL; Hillner BE; Fleishman S; Niell HB
J Clin Oncol; 1995 Sep; 13(9):2457-63. PubMed ID: 7545222
[TBL] [Abstract][Full Text] [Related]
5. The costs of conducting clinical research.
Emanuel EJ; Schnipper LE; Kamin DY; Levinson J; Lichter AS
J Clin Oncol; 2003 Nov; 21(22):4145-50. PubMed ID: 14559889
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of cancer therapies: more and better studies will lead to better choices in cancer care.
Uyl-de Groot CA
Eur J Cancer; 2006 Nov; 42(17):2862-6. PubMed ID: 17008095
[TBL] [Abstract][Full Text] [Related]
7. Measuring the incremental cost of clinical cancer research.
Goldman DP; Schoenbaum ML; Potosky AL; Weeks JC; Berry SH; Escarce JJ; Weidmer BA; Kilgore ML; Wagle N; Adams JL; Figlin RA; Lewis JH; Cohen J; Kaplan R; McCabe M
J Clin Oncol; 2001 Jan; 19(1):105-10. PubMed ID: 11134202
[TBL] [Abstract][Full Text] [Related]
8. Clinical trials: are they a good buy?
Bennett CL; Adams JR; Knox KS; Kelahan AM; Silver SM; Bailes JS
J Clin Oncol; 2001 Dec; 19(23):4330-9. PubMed ID: 11731516
[TBL] [Abstract][Full Text] [Related]
9. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results.
Elting LS; Shih YC; Stiff PJ; Bensinger W; Cantor SB; Cooksley C; Spielberger R; Emmanoulides C
Biol Blood Marrow Transplant; 2007 Jul; 13(7):806-13. PubMed ID: 17580258
[TBL] [Abstract][Full Text] [Related]
10. Economic analysis in phase III clinical cancer trials.
Bennett CL; Armitage JL; Buchner D; Gulati S
Cancer Invest; 1994; 12(3):336-42. PubMed ID: 8187012
[TBL] [Abstract][Full Text] [Related]
11. Economic considerations in comparing whole abdominal radiotherapy with combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: how much economic data should be collected?
Weeks JC
J Natl Cancer Inst Monogr; 1995; (19):17-9. PubMed ID: 7577199
[TBL] [Abstract][Full Text] [Related]
12. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
13. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
Allen D; Rixson L
Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
[TBL] [Abstract][Full Text] [Related]
14. Beware the Medical-Industrial Complex.
Stevens CW; Glatstein E
Oncologist; 1996; 1(4):IV-V. PubMed ID: 10388005
[TBL] [Abstract][Full Text] [Related]
15. Reducing the costs of phase III cardiovascular clinical trials.
Eisenstein EL; Lemons PW; Tardiff BE; Schulman KA; Jolly MK; Califf RM
Am Heart J; 2005 Mar; 149(3):482-8. PubMed ID: 15864237
[TBL] [Abstract][Full Text] [Related]
16. Economic Evaluations in National Cancer Institute-Sponsored Network Cancer Clinical Trials.
Nghiem VT; Vaidya R; Lyman GH; Hershman DL; Ramsey SD; Unger JM
Value Health; 2020 Dec; 23(12):1653-1661. PubMed ID: 33248521
[TBL] [Abstract][Full Text] [Related]
17. Economic analyses of clinical trials in cancer: are they helpful to policy makers?
Bennett CL; Armitage JL; LeSage S; Gulati SC; Armitage JO; Gorin NC
Stem Cells; 1994 Jul; 12(4):424-9. PubMed ID: 7951008
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness as an outcome in randomized clinical trials.
Hlatky MA; Owens DK; Sanders GD
Clin Trials; 2006; 3(6):543-51. PubMed ID: 17170039
[TBL] [Abstract][Full Text] [Related]
19. Taking quality of life into account in health economic analyses.
Weeks J
J Natl Cancer Inst Monogr; 1996; (20):23-7. PubMed ID: 8750463
[TBL] [Abstract][Full Text] [Related]
20. Pharmacoeconomics: an emerging discipline.
Letizia C
Qual Assur; 1995 Mar; 4(1):68-74. PubMed ID: 8520866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
